Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
592 participants
OBSERVATIONAL
2023-05-29
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Metabolic Remodeling in Shock
NCT06285513
The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit
NCT05415332
Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients
NCT01089036
Microcirculation in Cardiogenic Shock
NCT03436641
Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction
NCT05148117
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
LV regional hypokinesia during critical illness may have several possible aetiologies, including ischemic, inflammatory or other/mixed processes. Of these, acute coronary artery obstruction is probably most important. Patients with sepsis, for example, and acute ST elevation myocardial infarction have twice the risk of death. Type II myocardial infarction can also lead to LV dysfunction due to insufficient coronary artery flow e.g., from tachycardia, hypotension and hypoxia, resulting in myocardial ischemia. In the absence of CAD, LV regional hypokinesia could also result from myocardial inflammation secondary to systemic inflammatory response, direct toxic effects of cytokines or pathogenic infiltration. Another possible aetiology is Takotsubo syndrome, an acute cardiac condition characterised by reversible regional hypokinesia, usually in the apical portion of the LV. The current paradigm suggests that Takotsubo syndrome is triggered by the overstimulation of the myocardium by catecholamines and is closely correlated to events involving severe emotional or physical stress. Cardiac dysfunction in critical illness is likely a phenotype of Takotsubo syndrome since patients in the ICU undergo extreme stress and are exposed to both endogenously-released and exogenously-administered catecholamines.
In critical illness, accurate diagnosis of LV dysfunction is challenging due to the similar clinical presentation of potential aetiologies. However, diagnosing the underlying aetiology of LV dysfunction is essential to provide appropriate treatment and optimise outcomes. CAD can be diagnosed with coronary angiography and cardiac computed tomography (CCT). In the absence of CAD, cMRI is useful. cMRI can differentiate between myocardial ischemia, and inflammation, as well as between an acute or past event.
In this study, patients are examined with echocardiography to identify those with cardiac dysfunction. In a sub-set of patients with LV dysfunction, patients will be examined with coronary CT (if no angiography performed) and cardiac MRI. Blood samples are collected for storage in biobank.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal left ventricular systolic function
Patients with normal echocardiographic systolic function, defined as having left ventricular ejection fraction ≥ 50% and no regional hypokinesia
Echocardiography
All patients in the study will be examined with echocardiography
Left ventricular dysfunction
Patients with echocardiographic left ventricular systolic dysfunction, defines as having left ventricular ejection fraction \< 50% or left ventricular regional hypokinesia in at least two adjacent segments
Echocardiography
All patients in the study will be examined with echocardiography
Cardiac magnetic resonance imaging
Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
Coronary CT
Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echocardiography
All patients in the study will be examined with echocardiography
Cardiac magnetic resonance imaging
Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
Coronary CT
Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admitted to a participating ICU within 24 hours
3. Significant organ dysfunction involving at least two organ systems. This is defined as fulfilling both of the following:
* At least 4 points on the SOFA scale (Sequential Organ Failure Assessment scale)
* Having at least 1 point on the SOFA scale from at least two organ systems
4. Given informed consent from patient or permission to participate from next of kin
Exclusion Criteria
2. Not being examined with echocardiography within 24 hours from inclusion
3. Retracted consent to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sahlgrenska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonatan Oras
Associate professor/Senior consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sahgrensak University Hospital
Västra Frölunda, Please Select, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCCCS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.